Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
CONCLUSIONS: Belzutifan continued to show robust activity and manageable safety in VHL disease-associated pNETs.PMID:38393723 | DOI:10.1158/1078-0432.CCR-23-2592
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tobias Else Eric Jonasch Othon Lliopoulos Kathryn E Beckermann Vivek Narayan Benjamin L Maughan Stephane Oudard Jodi K Maranchie Ane B Iversen Cynthia Muller Goldberg Wei Fu Rodolfo F Perini Yanfang Liu W Marston Linehan Ramaprasad Srinivasan Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Carcinoma | Cystadenoma | Kidney Cancer | Neurology | Neurosurgery | Pancreas | Pancreatic Cancer | Renal Cell Carcinoma | Serous Carcinoma | Study